Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Sirnaomics Ltd. ( ($HK:2257) ) has issued an announcement. Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Nasdaq-100 is reconstituted each year in December, timed to coincide with the quadruple witch expiration on the Friday of ...

That’s because the industry veteran will join Alnylam’s board as of Jan. 5. Arbuckle had been executive vice president and ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

B.C. is reviewing whether to fund an expensive drug for patients who have a genetic condition that causes dangerously high ...

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice ...